EGFR inhibition has also been linked to the transient downregulation of mismatch repair (MLH1, MSH2, and MSH6) and HR (BRCA2, RAD51) genes in cetuximab-sensitive colorectal cancer cell lines, increasing the mutability that leads to the development of permanent resistance with prolonged exposure [147]. The gene discussed is EGFR; the disease is colorectal cancer.